Government-Owned Inventions; Availability for Licensing, 10778-10779 [2017-03017]
Download as PDF
10778
Federal Register / Vol. 82, No. 30 / Wednesday, February 15, 2017 / Notices
Committee shall be made without
discrimination on the basis of age, race,
ethnicity, gender, sexual orientation,
disability, and cultural, religious, or
socioeconomic status. Requests for
reasonable accommodation to enable
participation on the Committee should
be indicated in the nomination
submission.
Member Terms: Non-Federal public
members of the Committee serve for a
term of 3 years, and may serve for an
unlimited number of terms if
reappointed. Members may serve after
the expiration of their terms, until their
successors have taken office.
Meetings and Travel: As specified by
Pub. L. 113–166, the MDCC ‘‘shall meet
no fewer than two times per calendar
year.’’ Travel expenses are provided for
non-federal public Committee members
to facilitate attendance at in-person
meetings. Members are expected to
make every effort to attend all full
committee meetings, twice per year,
either in person or via remote access.
Participation in relevant subcommittee,
working and planning group meetings,
and workshops, is also encouraged.
Submission Instructions and
Deadline: Nominations are due by 5
p.m. EST on March 17, 2017, and
should be sent to Glen Nuckolls, Ph.D.,
by email to nuckollg@ninds.nih.gov.
Nominations must include contact
information for the nominee, a current
curriculum vitae or resume of the
nominee and a paragraph describing the
qualifications of the person to represent
some portion(s) of the muscular
dystrophy research, advocacy and/or
patient care communities.
More information about the MDCC is
available at https://mdcc.nih.gov/.
Dated: February 10, 2017.
Walter J. Koroshetz,
Director, National Institute of Neurological
Disorders and Stroke, National Institutes of
Health.
[FR Doc. 2017–03018 Filed 2–14–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
mstockstill on DSK3G9T082PROD with NOTICES
National Institutes of Health
Center for Scientific Review; Amended
Notice of Meeting
Notice is hereby given of a change in
the meeting of the Genetic Variation and
Evolution Study Section, February 16,
2017, 08:00 a.m. to February 17, 2017,
07:00 p.m., Renaissance M Street Hotel,
1143 New Hampshire Avenue NW.,
Washington, DC 20037 which was
VerDate Sep<11>2014
18:44 Feb 14, 2017
Jkt 241001
published in the Federal Register on
January 23, 2017, 82 FR 7842.
The meeting will be held on 02/17/
2017 instead of 02/16/2017–02/17/2017.
The meeting time and location remains
the same. The meeting is closed to the
public.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Dated: February 9, 2017.
David Clary,
Program Analyst, Office of Federal Advisory
Committee Policy.
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
[FR Doc. 2017–03013 Filed 2–14–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Biomedical
Imaging and Bioengineering; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Biomedical Imaging and Bioengineering
Special Emphasis Panel; K Award—R13
Review Meeting (2017/05).
Date: March 9, 2017.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, Suite 920, 6707 Democracy
Boulevard, Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: John K. Hayes, Ph.D.,
Scientific Review Officer, 6707 Democracy
Boulevard, Suite 959, Democracy Two,
Bethesda, MD 20892, (301) 451–3398,
hayesj@mail.nih.gov.
Dated: February 9, 2017.
David Clary,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–03012 Filed 2–14–17; 8:45 am]
BILLING CODE 4140–01–P
PO 00000
Frm 00045
Fmt 4703
Sfmt 4703
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Name of Committee: Microbiology,
Infectious Diseases and AIDS Initial Review
Group; Microbiology and Infectious Diseases
B Subcommittee MID–B March 2017.
Date: March 6–7, 2017.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Marriott Courtyard Gaithersburg
Washingtonian Center, 204 Boardwalk Place,
Gaithersburg, MD 20878.
Contact Person: Ellen S. Buczko, Ph.D.,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
National Institutes of Health/NIAID, 6700B
Rockledge Drive, MSC 7616, Bethesda, MD
20892–7616, 301–451–2676, ebuczko1@
niaid.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: February 9, 2017.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–03014 Filed 2–14–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The invention listed below is
owned by an agency of the U.S.
Government and is available for
SUMMARY:
E:\FR\FM\15FEN1.SGM
15FEN1
Federal Register / Vol. 82, No. 30 / Wednesday, February 15, 2017 / Notices
mstockstill on DSK3G9T082PROD with NOTICES
licensing to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
FOR FURTHER INFORMATION CONTACT:
Licensing information and copies of the
patent applications listed below may be
obtained by communicating with the
indicated licensing contact at the
Technology Transfer and Intellectual
Property Office, National Institute of
Allergy and Infectious Diseases, 5601
Fishers Lane, Rockville, MD 20852; tel.
301–496–2644. A signed Confidential
Disclosure Agreement will be required
to receive copies of unpublished patent
applications.
SUPPLEMENTARY INFORMATION:
Technology description follows.
Synergistic Internal Ribosomal Entry
Site (IRES)—MicroRNA-Based
Approach for Attenuation of
Flaviviruses and Live Vaccine
Development
Description of Technology: Many
members of the Flaviviridae family are
emerging and reemerging human
pathogens that have caused outbreaks of
devastating and often fatal diseases and
represent a serious public health
problem on a global scale. There is no
single attenuation strategy that exists
which is sufficient to prepare a safe,
efficacious and immunogenic live
attenuated virus vaccine that will work
universally for Flaviviridae. This patent
application claims live attenuated
flavivirus vaccines, live attenuated
multivalent flavivirus vaccines, and
methods of preventing flavivirus
infections as well as methods of making
the vaccines claimed in the application.
More specifically, this patent
application claims methods for
attenuating a flavivirus or chimeric
flavivirus using a synergistic dual
strategy involving inserting miRNAtargeting sequences to restrict virus
replication in target hosts, cells and/or
tissues and placing one or more
flavivirus genes under translational
control of an internal ribosomal entry
site (IRES).
This technology is available for
licensing for commercial development
in accordance with 35 U.S.C. 209 and 37
CFR part 404, as well as for further
development and evaluation under a
research collaboration.
Potential Commercial Applications:
• Diagnostics
• Vaccines
Competitive Advantages:
VerDate Sep<11>2014
18:44 Feb 14, 2017
Jkt 241001
•
•
•
•
Potential one-dose flavivirus vaccine
Ease of manufacture in Vero cells
Low-cost potential vaccine
Developing and developed world
potential vaccines
Development Stage:
• In vivo data available (animal)
Inventors: Alexander Pletnev (NIAID),
Konstantin Tsetsarkin (NIAID).
Intellectual Property: HHS Reference
No. E–006–2017/0—U.S. Provisional
Application No. 62/443,214, filed
January 6, 2017.
Licensing Contact: Peter Soukas, J.D.,
301–594–8730; peter.soukas@nih.gov.
Collaborative Research Opportunity:
The National Institute of Allergy and
Infectious Diseases is seeking statements
of capability or interest from parties
interested in collaborative research to
further develop, evaluate or
commercialize vaccine(s) for
prophylaxis against flavivirus
infections. For collaboration
opportunities, please contact Peter
Soukas, J.D., 301–594–8730;
peter.soukas@nih.gov.
Dated: February 6, 2017.
Suzanne Frisbie,
Deputy Director, Technology Transfer and
Intellectual Property Office, National Institute
of Allergy and Infectious Diseases.
[FR Doc. 2017–03017 Filed 2–14–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The invention listed below is
owned by an agency of the U.S.
Government and is available for
licensing to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
FOR FURTHER INFORMATION CONTACT:
Licensing information and copies of the
patent applications listed below may be
obtained by communicating with the
indicated licensing contact at the
Technology Transfer and Intellectual
Property Office, National Institute of
Allergy and Infectious Diseases, 5601
Fishers Lane, Rockville, MD 20852; tel.
SUMMARY:
PO 00000
Frm 00046
Fmt 4703
Sfmt 4703
10779
301–496–2644. A signed Confidential
Disclosure Agreement will be required
to receive copies of unpublished patent
applications.
SUPPLEMENTARY INFORMATION:
Technology description follows.
A Bivalent Conjugate Vaccine for
Malaria and Typhoid Prophylaxis
Description of Technology: Malaria is
the single leading cause of mortality,
especially among children in the
developing world. Typhoid fever,
caused by infection with Salmonella
typhi, is known to be endemic with
malaria and causes its own significant
disease burden. Scientists at the
National Institute of Allergy and
Infectious Diseases (NIAID), part of the
National Institutes of Health, have
developed a novel bivalent vaccine
candidate that may effectively prevent
malaria and typhoid. This approach
significantly enhances immune
response to the Pfs25 Malaria
transmission blocking antigen and
produces a robust immune response
against Salmonella typhi Vi
polysaccharide (ViP).
This technology is available for
licensing for commercial development
in accordance with 35 U.S.C. 209 and 37
CFR part 404, as well as for further
development and evaluation under a
research collaboration.
Potential Commercial Applications:
• Development of this technology
into a vaccine may protect vulnerable
populations from both Malaria
transmission and Typhoid fever.
Competitive Advantages:
• This technology has significant
advantages over current treatments,
since there is currently only one
commercial Malaria vaccine licensed for
use in Europe only, which was not
developed to address Malaria
transmission, and the currently licensed
Salmonella typhi vaccines show
incomplete efficacy and do not provide
long-term immunity. A formulation of
the present technology has shown the
ability to induce an immune response to
Pfs25 in excess of 100 times higher and
Salmonella typhi antigen 20–40 times
higher than what is seen by
immunization with either antigen alone.
Development Stage:
• In vivo data available (animal).
Inventors: Drs. Patrick Duffy, Sojung
An, and Puthupparampil Scaria, NIAID,
NIH.
Publications: None.
Intellectual Property: Provisional
Patent application #62/327,184 Filed
04/25/16, Technology reference #E–
124–2016/0.
E:\FR\FM\15FEN1.SGM
15FEN1
Agencies
[Federal Register Volume 82, Number 30 (Wednesday, February 15, 2017)]
[Notices]
[Pages 10778-10779]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-03017]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The invention listed below is owned by an agency of the U.S.
Government and is available for
[[Page 10779]]
licensing to achieve expeditious commercialization of results of
federally-funded research and development. Foreign patent applications
are filed on selected inventions to extend market coverage for
companies and may also be available for licensing.
FOR FURTHER INFORMATION CONTACT: Licensing information and copies of
the patent applications listed below may be obtained by communicating
with the indicated licensing contact at the Technology Transfer and
Intellectual Property Office, National Institute of Allergy and
Infectious Diseases, 5601 Fishers Lane, Rockville, MD 20852; tel. 301-
496-2644. A signed Confidential Disclosure Agreement will be required
to receive copies of unpublished patent applications.
SUPPLEMENTARY INFORMATION: Technology description follows.
Synergistic Internal Ribosomal Entry Site (IRES)--MicroRNA-Based
Approach for Attenuation of Flaviviruses and Live Vaccine Development
Description of Technology: Many members of the Flaviviridae family
are emerging and reemerging human pathogens that have caused outbreaks
of devastating and often fatal diseases and represent a serious public
health problem on a global scale. There is no single attenuation
strategy that exists which is sufficient to prepare a safe, efficacious
and immunogenic live attenuated virus vaccine that will work
universally for Flaviviridae. This patent application claims live
attenuated flavivirus vaccines, live attenuated multivalent flavivirus
vaccines, and methods of preventing flavivirus infections as well as
methods of making the vaccines claimed in the application. More
specifically, this patent application claims methods for attenuating a
flavivirus or chimeric flavivirus using a synergistic dual strategy
involving inserting miRNA-targeting sequences to restrict virus
replication in target hosts, cells and/or tissues and placing one or
more flavivirus genes under translational control of an internal
ribosomal entry site (IRES).
This technology is available for licensing for commercial
development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as
well as for further development and evaluation under a research
collaboration.
Potential Commercial Applications:
Diagnostics
Vaccines
Competitive Advantages:
Potential one-dose flavivirus vaccine
Ease of manufacture in Vero cells
Low-cost potential vaccine
Developing and developed world potential vaccines
Development Stage:
In vivo data available (animal)
Inventors: Alexander Pletnev (NIAID), Konstantin Tsetsarkin
(NIAID).
Intellectual Property: HHS Reference No. E-006-2017/0--U.S.
Provisional Application No. 62/443,214, filed January 6, 2017.
Licensing Contact: Peter Soukas, J.D., 301-594-8730;
peter.soukas@nih.gov.
Collaborative Research Opportunity: The National Institute of
Allergy and Infectious Diseases is seeking statements of capability or
interest from parties interested in collaborative research to further
develop, evaluate or commercialize vaccine(s) for prophylaxis against
flavivirus infections. For collaboration opportunities, please contact
Peter Soukas, J.D., 301-594-8730; peter.soukas@nih.gov.
Dated: February 6, 2017.
Suzanne Frisbie,
Deputy Director, Technology Transfer and Intellectual Property Office,
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2017-03017 Filed 2-14-17; 8:45 am]
BILLING CODE 4140-01-P